Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Roche-FDA-Grants-Priority-Review-to-Genentech-s-Polatuzumab-Vedotin-in-Previously-Treated-Aggres-28028034/?utm_source=whatsapp&utm_medium=social&utm_campaign=share